These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33914350)

  • 21. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
    Poveda A; Oaknin A; Romero I; Guerrero-Zotano A; Fariñas-Madrid L; Rodriguez-Freixinos V; Mallol P; Lopez-Reig R; Lopez-Guerrero JA
    Sci Rep; 2021 Feb; 11(1):4433. PubMed ID: 33627685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
    Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
    J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.
    van Hasselt JG; Gupta A; Hussein Z; Beijnen JH; Schellens JH; Huitema AD
    Br J Clin Pharmacol; 2013 Sep; 76(3):412-24. PubMed ID: 23601153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
    Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
    Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB
    Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.
    Moreno I; Hernández T; Calvo E; Fudio S; Kahatt C; Martínez S; Iglesias JL; Calafati RO; Pérez-Ramos L; Montilla L; Zeaiter A; Lubomirov R
    Mar Drugs; 2024 Apr; 22(4):. PubMed ID: 38667795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T; Kasai H; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
    Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
    Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
    Yang BB; Kido A
    Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
    Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
    Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.
    Valenzuela B; Nalda-Molina R; Bretcha-Boix P; Escudero-Ortíz V; Duart MJ; Carbonell V; Sureda M; Rebollo JP; Farré J; Brugarolas A; Pérez-Ruixo JJ
    AAPS J; 2011 Mar; 13(1):72-82. PubMed ID: 21210260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
    Mross K; Scheulen ME; Licht T; Unger C; Richly H; Stern AC; Kutz K; Camboni MG; Barbieri P; Verdi E; Vincenzi B; Bernareggi A
    Anticancer Drugs; 2004 Jan; 15(1):15-22. PubMed ID: 15090738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
    Cohen RB; Jones SF; Aggarwal C; von Mehren M; Cheng J; Spigel DR; Greco FA; Mariani M; Rocchetti M; Ceruti R; Comis S; Laffranchi B; Moll J; Burris HA
    Clin Cancer Res; 2009 Nov; 15(21):6694-701. PubMed ID: 19825950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.
    Neelis KJ; Hartong SC; Egeland T; Thomas GR; Eaton DL; Wagemaker G
    Blood; 1997 Oct; 90(7):2565-73. PubMed ID: 9326222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.